|
Demographics
|
|
Male (n (%))
|
40 (95.2%)
|
|
Age (years)
|
63 ± 13.2
|
|
Gout duration (years)
|
7.9 ± 9.6
|
|
Familial gout (n (%))
|
7 (16.7%)
|
|
Number of flares per year
|
4.1 ± 6.6
|
|
Alcohol consumption (g/day)
|
15 ± 20.7
|
|
Creatinine clearance (ml/min)
|
80.0 ± 31.1
|
|
Cardiovascular risk factors
|
|
Body mass index (kg/m2)
|
30.2 ± 5.7
|
|
Total cholesterol (mg/dL)
|
177 ± 63
|
|
HDL cholesterol (mg/dL)
|
44 ± 13
|
|
LDL cholesterol (mg/dL)
|
97 ± 43
|
|
Triglycerides (mg/dL)
|
207 ± 393
|
|
Systolic blood pressure (mmHg)
|
132.8 ± 13.7
|
|
Diastolic blood pressure (mmHg)
|
77 ± 9.9
|
|
Smoker (n (%))
|
6 (14.3%)
|
|
Metabolic syndrome (n (%))
|
28 (66.7%)
|
|
Cardiovascular comorbidities
|
|
Coronary heart disease (n (%))
|
6 (14.3%)
|
|
Peripheral arterial disease (n (%))
|
3 (7.1%)
|
|
Stroke (n (%))
|
3 (7.1%)
|
|
Diabetes mellitus (n (%))
|
15 (35.7%)
|
|
Cardiovascular risk assessment
|
|
ACC/AHA 10-year risk (%)
|
21 ± 14
|
|
Framingham 10-year general cardiovascular risk (%)
|
22 ± 14
|
|
Framingham 10-year coronary risk (%)
|
15 ± 11
|
|
Urate burden
|
|
Serum urate (mg/dL)
|
8.1 ± 2.3
|
|
Subcutaneous (clinical) tophi (n (%))
|
12 (28.6%)
|
|
Ultrasound tophus (n (%))
|
29 (69%)
|
|
Ultrasound tophus volume (cm3)
|
1.1 ± 1.4
|
|
At least one joint with the double contour sign (n (%))
|
41 (97.6%)
|
|
DECT MSU volume knees (cm3) (n = 39)
|
1.9 ± 4.6
|
|
DECT MSU volume feet (cm3) (n = 41)
|
2.7 ± 6.7
|
|
DECT MSU volume knees + feet (cm3) (n = 38)
|
4.7 ± 10.8
|
|
Ongoing drugs
|
|
Diuretics (n (%))
|
11 (26.2%)
|
|
Antidiabetic treatment (n (%))
|
15 (35.7%)
|
|
Hypolipidemic treatment (n (%))
|
16 (38.1%)
|
|
Treatment for high blood pressure (n (%))
|
25 (59.5%)
|
